Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network

Abstract

Background

Implementation methods of risk-stratified cancer screening guidance throughout a health care system remains understudied.

Objective

Conduct a preliminary analysis of the implementation of a risk-stratified prostate cancer screening algorithm in a single health care system.

Design

Comparison of men seen pre-implementation (2/1/2016–2/1/2017) vs. post-implementation (2/2/2017–2/21/2018).

Participants

Men, aged 40–75 years, without a history of prostate cancer, who were seen by a primary care provider.

Interventions

The algorithm was integrated into two components in the electronic health record (EHR): in Health Maintenance as a personalized screening reminder and in tailored messages to providers that accompanied prostate-specific antigen (PSA) results.

Main Measures

Primary outcomes: percent of men who met screening algorithm criteria; percent of men with a PSA result. Logistic repeated measures mixed models were used to test for differences in the proportion of individuals that met screening criteria in the pre- and post-implementation periods with age, race, family history, and PSA level included as covariates.

Key Results

During the pre- and post-implementation periods, 49,053 and 49,980 men, respectively, were seen across 26 clinics (20.6% African American). The proportion of men who met screening algorithm criteria increased from 49.3% (pre-implementation) to 68.0% (post-implementation) (p < 0.001); this increase was observed across all races, age groups, and primary care clinics. Importantly, the percent of men who had a PSA did not change: 55.3% pre-implementation, 55.0% post-implementation. The adjusted odds of meeting algorithm-based screening was 6.5-times higher in the post-implementation period than in the pre-implementation period (95% confidence interval, 5.97 to 7.05).

Conclusions

In this preliminary analysis, following implementation of an EHR-based algorithm, we observed a rapid change in practice with an increase in screening in higher-risk groups balanced with a decrease in screening in low-risk groups. Future efforts will evaluate costs and downstream outcomes of this strategy.

This is a preview of subscription content, access via your institution.

Figure 1

References

  1. 1.

    Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975-2016. National Cancer Institute. Bethesda, April 2019. https://seer.cancer.gov/csr/1975_2016/.

  2. 2.

    Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69:7-34, 2019

    Article  Google Scholar 

  3. 3.

    Schroder FH, Hugosson J, Roobol MJ, et al: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027-35, 2014

    Article  Google Scholar 

  4. 4.

    Fenton JJ, Weyrich MS, Durbin S, et al: Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 319:1914-1931, 2018

    Article  Google Scholar 

  5. 5.

    Gomella LG, Liu XS, Trabulsi EJ, et al: Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol 18:5875-83, 2011

    PubMed  Google Scholar 

  6. 6.

    Burns RB, Olumi AF, Owens DK, et al: Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med 170:770-778, 2019

    Article  Google Scholar 

  7. 7.

    Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 102:605-13, 2010

    Article  Google Scholar 

  8. 8.

    Moyer VA, Force USPST: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-34, 2012

    Article  Google Scholar 

  9. 9.

    Smith RA, Manassaram-Baptiste D, Brooks D, et al: Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 64:30-51, 2014

    Article  Google Scholar 

  10. 10.

    Mohler JL, Kantoff PW, Armstrong AJ, et al: Prostate cancer, version 2.2014. J Natl Compr Cancer Netw 12:686-718, 2014

    CAS  Article  Google Scholar 

  11. 11.

    Jemal A, Fedewa SA, Ma J, et al: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA 314:2054-61, 2015

    CAS  Article  Google Scholar 

  12. 12.

    Houston KA, King J, Li J, et al: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013. J Urol 199:676-682, 2018

    Article  Google Scholar 

  13. 13.

    Pinsky PF, Prorok PC, Kramer BS: Prostate Cancer Screening - A Perspective on the Current State of the Evidence. N Engl J Med 376:1285-1289, 2017

    Article  Google Scholar 

  14. 14.

    Pinsky PF, Prorok PC, Yu K, et al: Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 123:592-599, 2017

    Article  Google Scholar 

  15. 15.

    Force USPST, Grossman DC, Curry SJ, et al: Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 319:1901-1913, 2018

    Article  Google Scholar 

  16. 16.

    Andriole GL, Crawford ED, Grubb RL, 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-9, 2009

    CAS  Article  Google Scholar 

  17. 17.

    DeSantis CE, Miller KD, Goding Sauer A, et al: Cancer statistics for African Americans, 2019. CA Cancer J Clin 69:211-233, 2019

    Article  Google Scholar 

  18. 18.

    Smith RA, Andrews KS, Brooks D, et al: Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 68:297-316, 2018

    Article  Google Scholar 

  19. 19.

    Mohler JL, Antonarakis ES, Armstrong AJ, et al: Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 17:479-505, 2019

    CAS  Article  Google Scholar 

  20. 20.

    Vickers AJ, Cronin AM, Bjork T, et al: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341:c4521, 2010

    Article  Google Scholar 

  21. 21.

    Vickers AJ, Ulmert D, Sjoberg DD, et al: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 346:f2023, 2013

    Article  Google Scholar 

  22. 22.

    Preston MA, Batista JL, Wilson KM, et al: Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 34:2705-11, 2016

    CAS  Article  Google Scholar 

  23. 23.

    Aminsharifi A, Schulman A, Anderson J, et al: Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in the electronic health record. Urol Oncol 36:502.e1-502.e6, 2018

    Article  Google Scholar 

  24. 24.

    Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-13, 2012

    CAS  Article  Google Scholar 

  25. 25.

    Wilt TJ, Jones KM, Barry MJ, et al: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 377:132-142, 2017

    Article  Google Scholar 

  26. 26.

    Parker CC, James ND, Brawley CD, et al: Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353-2366, 2018

    Article  Google Scholar 

  27. 27.

    Sydes MR, Spears MR, Mason MD, et al: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 29:1235-1248, 2018

    CAS  Article  Google Scholar 

  28. 28.

    Bill-Axelson A, Holmberg L, Garmo H, et al: Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med 379:2319-2329, 2018

    Article  Google Scholar 

  29. 29.

    Bates D, Machler M, Bolker BM, et al: Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw 67:1-48, 2015

    Article  Google Scholar 

  30. 30.

    R Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2018. https://www.R-project.org/

  31. 31.

    Merlo J, Chaix B, Ohlsson H, et al: A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health 60:290-7, 2006

    Article  Google Scholar 

  32. 32.

    Krumholz HM, Radford MJ, Wang Y, et al: National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 280:623-9, 1998

    CAS  Article  Google Scholar 

  33. 33.

    Sial SH, Malone M, Freeman JL, et al: Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med 9:599-605, 1994

    CAS  Article  Google Scholar 

  34. 34.

    Ayanian JZ, Hauptman PJ, Guadagnoli E, et al: Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 331:1136-42, 1994

    CAS  Article  Google Scholar 

  35. 35.

    Grol R, Grimshaw J: From best evidence to best practice: effective implementation of change in patients’ care. Lancet 362:1225-1230, 2003

    Article  Google Scholar 

  36. 36.

    Fischer F, Lange K, Klose K, Greiner W, Kraemer A: Barriers and strategies in guideline Implementation-A Scoping Review. Healthcare (Basel)4(3):36, 2016. https://doi.org/10.3390/healthcare4030036.

  37. 37.

    Dowding D, Randell R, Gardner P, et al: Dashboards for improving patient care: review of the literature. Int J Med Inform 84:87-100, 2015

    Article  Google Scholar 

  38. 38.

    Twohig PA, Rivington JR, Gunzler D, et al: Clinician dashboard views and improvement in preventative health outcome measures: a retrospective analysis. BMC Health Serv Res 19:475, 2019

    Article  Google Scholar 

  39. 39.

    Baron RC, Melillo S, Rimer BK, et al: Intervention to increase recommendation and delivery of screening for breast, cervical, and colorectal cancers by healthcare providers a systematic review of provider reminders. Am J Prev Med 38:110-7, 2010

    Article  Google Scholar 

  40. 40.

    Jun T, Kwang H, Mou E, et al: An Electronic Best Practice Alert Based on Choosing Wisely Guidelines Reduces Thrombophilia Testing in the Outpatient Setting. J Gen Intern Med 34:29-30, 2019

    Article  Google Scholar 

  41. 41.

    Ancker JS, Edwards A, Nosal S, et al: Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system. BMC Med Inform Decis Mak 17:36, 2017

    Article  Google Scholar 

  42. 42.

    Brown B, Young J, Smith DP, et al: A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: A stepped-wedge cluster randomised implementation trial. Implement Sci 13(1):43, 2016. https://doi.org/10.1186/s13012-018-0733-x.

  43. 43.

    Preston MA, Gerke T, Carlsson SV, et al: Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol 75:399-407, 2019

    CAS  Article  Google Scholar 

  44. 44.

    Guise JM, Savitz LA, Friedman CP: Mind the Gap: Putting Evidence into Practice in the Era of Learning Health Systems. J Gen Intern Med 33:2237-2239, 2018

    Article  Google Scholar 

  45. 45.

    Nwaru BI, Friedman C, Halamka J, et al: Can learning health systems help organisations deliver personalised care? BMC Med 15:177, 2017

    Article  Google Scholar 

Download references

Funding

This work was supported by grants from the National Cancer Institute (P30CA014236) and the Duke Institute for Health Innovation (DIHI).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kevin Shah MD, MBA.

Ethics declarations

This study was reviewed and deemed exempt by the Duke Institutional Review Board.

Conflict of Interest

Thomas J. Polascik reports consultancies in the last 3 years and honoraria in the last 3 years from Healthtronics [training agreement]. Terry Hyslop reports consultancies in the last 3 years from AbbVie. Glenn M. Preminger reports consultancies in the last 3 years from Boston Scientific, Auris Robotics, and Kalera Medical and reports other relationships as an Associate Editor for Up to Date. Kevin Shah reports stock ownership/options other than mutual funds from Infinity Pharmaceuticals. Anand Shah reports stock ownership/options other than mutual funds from Pfizer Inc. All other authors report no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Previous Presentation

2019 Society of General Internal Medicine Annual Meeting

Electronic supplementary material

ESM 1

(PDF 462 kb)

ESM 2

(ZIP 20 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shah, A., Polascik, T.J., George, D.J. et al. Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network. J GEN INTERN MED 36, 92–99 (2021). https://doi.org/10.1007/s11606-020-06124-2

Download citation